Trials in India are already underway with Pegylated Interferon alpha-2b
Interferon alpha emerges as one of the treatment options for COVID 19; In vitro and in vivo studies suggest positive effects on COVID-19 Patients
Zydus Cadila, today announced that it had received approval from the Mexican regulatory authority COFEPRIS to conduct clinical trials with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. This will be an open-label, randomized, comparator controlled study of Pegylated IFN alfa-2b to evaluate safety, efficacy and tolerability in patients with COVID-19.
Clinical and regulatory development of Pegylated Interferon alpha-2b in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading Contract Research Organization (CRO) headquartered in Monterrey, Mexico.
Zydus had earlier approached the DCGI to investigate the role of Pegylated Interferon alpha-2b for COVID 19 and the clinical trials are now underway. The Company is also working with USFDA to open an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b.
“Our endeavour is to continue looking for pathways for a safe and efficacious treatment to combat COVID19. Pegylated Interferon alpha has the potential to reduce virus titres when given earlier in the disease. The focus is on reducing the viral load and generating virus eliminating specific immune response," said Speaking on the development, Dr. Sharvil Patel, Managing Director, Cadila Healthcare.
The treatment option emerged after the publication of two recent peer reviewed research articles. The first one by Ogando et al (Journal of General Virology, June 2020) at Leiden University Medical Center, Netherlands showed an evidence of a direct anti-viral effect of Pegylated Interferon alpha against novel Coronavirus.
The study demonstrated that Pegylated Interferon was able to completely neutralize SARSCoV-2 virus in vitro. The second by Zhou et al (Frontiers in Immunology, May 2020) from a group of universities in China, Australia and Canada retrospectively analysed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alpha-2b showed a significant reduction in the duration of virus shedding period and even in levels of the inflammatory cytokine, IL-6.